Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
HER2+ Breast Cancer and CDK4/6 Inhibitors
Related Items


TON Web Exclusives published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Last modified: January 11, 2018